Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Baird Medical Investment Holdings Limited (BDMD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: BDMD (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
0 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
Analysis of Past Performance
Type Stock | Historic Profit -20.62% | Avg. Invested days 65 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 234.17M USD | Price to earnings Ratio 18.4 | 1Y Target Price - |
Price to earnings Ratio 18.4 | 1Y Target Price - | ||
Volume (30-day avg) - | Beta -0.7 | 52 Weeks Range 1.05 - 12.75 | Updated Date 06/3/2025 |
52 Weeks Range 1.05 - 12.75 | Updated Date 06/3/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.35 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 37.96% | Operating Margin (TTM) 38.74% |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE 18.4 | Forward PE - | Enterprise Value 248186805 | Price to Sales(TTM) 7.09 |
Enterprise Value 248186805 | Price to Sales(TTM) 7.09 | ||
Enterprise Value to Revenue 7.51 | Enterprise Value to EBITDA 15.25 | Shares Outstanding 36362200 | Shares Floating 10638416 |
Shares Outstanding 36362200 | Shares Floating 10638416 | ||
Percent Insiders 22.16 | Percent Institutions 1.97 |
Upturn AI SWOT
Baird Medical Investment Holdings Limited
Company Overview
History and Background
Baird Medical Investment Holdings Limited focuses on the development, manufacturing, and sales of minimally invasive surgical devices, particularly in the areas of interventional oncology and vascular surgery. Founded in China, it has expanded its operations to serve a global market, including the US.
Core Business Areas
- Interventional Oncology: Development and sale of devices used in minimally invasive procedures to treat cancer, such as ablation systems and drug-delivery devices.
- Vascular Surgery: Development and sale of devices used in minimally invasive procedures for vascular diseases, such as peripheral artery disease and venous disorders.
- General Surgery: Development and sale of surgical devices used to diagnose, treat and prevent diseases and disorders.
Leadership and Structure
Leadership includes CEO, CFO, and heads of R&D, Sales, and Operations. The organizational structure is hierarchical, with departments dedicated to research, manufacturing, sales, and marketing.
Top Products and Market Share
Key Offerings
- Microwave Ablation (MWA) System: A minimally invasive device used to destroy tumors via heat. Competitors include Medtronic and Boston Scientific. Market share data not readily available in specific geographical locations.
- Radiofrequency Ablation (RFA) System: Another minimally invasive device for tumor ablation using radiofrequency energy. Competitors include AngioDynamics and Hologic. Market share data not readily available in specific geographical locations.
- Cryoablation System: Minimally invasive device used to destroy tumors via freezing. Competitors include Galil Medical and Boston Scientific. Market share data not readily available in specific geographical locations.
Market Dynamics
Industry Overview
The medical device industry is experiencing growth due to aging populations, technological advancements, and increasing demand for minimally invasive procedures. The oncology and vascular surgery segments are particularly strong.
Positioning
Baird Medical Investment Holdings Limited is positioned as a provider of minimally invasive surgical devices, competing with larger, established medical device companies. Its competitive advantage may lie in innovative technologies and cost-effective solutions within certain niche segments.
Total Addressable Market (TAM)
The global market for minimally invasive surgical instruments is projected to reach $45 billion by 2028. Baird Medical aims to capture a share of this market, focusing on specialized areas within oncology and vascular surgery.
Upturn SWOT Analysis
Strengths
- Innovative product portfolio
- Focus on minimally invasive procedures
- Potential for cost-effective solutions
- Established presence in China
Weaknesses
- Smaller scale compared to major competitors
- Limited brand recognition in certain markets
- Dependence on specific product lines
- Concentrated revenue streams
Opportunities
- Expanding market for minimally invasive procedures
- Growth in emerging markets
- Strategic partnerships and acquisitions
- Technological advancements in surgical devices
Threats
- Intense competition from established players
- Regulatory hurdles and approvals
- Price pressures from healthcare providers
- Technological obsolescence
Competitors and Market Share
Key Competitors
- MDT
- BSX
- ANGI
Competitive Landscape
Baird Medical competes with larger, more established medical device companies. It needs to differentiate itself through innovative products and cost-effective solutions.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by increasing demand for minimally invasive surgical procedures, particularly in the Chinese market.
Future Projections: Future growth is expected to be driven by expanding into new markets, developing new products, and strategic partnerships.
Recent Initiatives: Recent initiatives include expanding distribution networks and investing in R&D for new product development.
Summary
Baird Medical Investment Holdings Limited focuses on minimally invasive surgical devices with growth potential in oncology and vascular areas. It faces intense competition and regulatory hurdles but has opportunities through innovation and strategic partnerships. More data is needed to gauge the company's true potential and financial health. Baird must expand its brand to get more market share.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Information
- Market Research Reports
- Industry Analysis
- SEC Filings (where available)
Disclaimers:
This analysis is based on publicly available information and general industry knowledge. Actual financial performance and market conditions may vary. This is not financial advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Baird Medical Investment Holdings Limited
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2024-10-01 | Chairwoman of the Board of Directors & CEO Ms. Haimei Wu | ||
Sector Healthcare | Industry Medical Devices | Full time employees 143 | Website https://bairdmed.com |
Full time employees 143 | Website https://bairdmed.com | ||
Baird Medical Investment Holdings Limited, together with its subsidiaries, engages in research and development, manufacturing, and sales of microwave ablation and other medical devices in the People's Republic of China. It offers microwave ablation apparatus and needles, as well as microwave ablation apparatus approved for the treatment of live cancer and thyroid nodules, long microwave ablation needles, and fine microwave ablation needles through third-party distributors. Baird Medical Investment Holdings Limited was founded in 2012 and is based in Guangzhou, China.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.